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Introduction
Tuberculosis (TB) was the leading cause of death from a single 
infectious agent worldwide in 2019, accounting for 1.5 million 
deaths (1). One contributor to this burden of disease is the large 
reservoir of asymptomatic Mycobacterium tuberculosis (Mtb) infec-
tions that affects approximately a quarter of the world’s population 
(2). Despite this prevalence, some individuals show no evidence of 
Mtb infection even after heavy and prolonged exposures and may 
be considered relatively resistant to infection (3). Characterization 
of this Mtb resistance phenotype is an emerging area of research 
(4–12) that may uncover novel immunologic pathways amenable 
to host-directed therapy or vaccine development.
Latent Mtb infection (LTBI) is defined as a positive tuberculin 
skin test (TST) or interferon-γ (IFN-γ) release assay (IGRA) in an 
individual without clinical or radiographic evidence of TB. Individ-
uals who are resistant to LTBI (resisters [RSTRs]) have persistently 
negative TST/IGRA testing despite intense and prolonged aerosol 
exposure to Mtb (3). We and others have identified RSTR popula-
tions among household TB contacts in Uganda (7), India (5), the 
Gambia (6), Haiti (12), and Indonesia (9, 10). While immunolog-
ic profiling of these cohorts suggests differences between RSTR 
and LTBI phenotypes (4, 6, 10, 11), to date no immunologic RSTR 
signature emerged across studies, which may be due to heteroge-
neity in case definitions, genetic background, Mtb exposure, dura-
tion of follow-up, and types of immune profiling assays that were 
employed. To our knowledge, no studies compared responses in a 
single cell type across multiple, stringently defined RSTR cohorts 
where conserved pathways are more likely to be identified.
Resident alveolar macrophages and recruited monocyte- 
derived macrophages are early targets of Mtb in the lung (13–15) 
and poised to play central roles in resistance phenotypes such as 
early innate clearance or the priming of alternative T cell respons-
es (3, 4). In the current study, we aimed to find conserved mono-
cyte immunologic signatures across 2 distinct RSTR cohorts, each 
of which had lengthy follow-up after high Mtb exposure. In Ugan-
da, we enrolled household contacts of pulmonary TB cases and 
followed them for 8 to 10 years with serial TST and IGRA testing 
(7, 8). In South Africa, we enrolled gold miners who had worked ≥ 
15 years in the mining industry, an environment with documented 
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In these Ugandan and South African cohorts, we identified 
monocyte transcriptional profiles that distinguish RSTR and LTBI 
populations and that suggest differences in central carbon metab-
olism and free fatty acid (FFA) signaling pathways. Furthermore, 
we identify associations between polymorphisms in a gene encod-
ing the metabolic regulator AMPK and the RSTR phenotype. Met-
abolic shifts are increasingly recognized as relevant to both Mtb 
extreme levels of Mtb transmission due to employment conditions 
in confined spaces, congregate living arrangements, and comor-
bid conditions including HIV and silicosis, among other factors 
(16, 17). Among these gold miner subjects, where LTBI prevalence 
has been measured at 89% (17) with an annual risk of infection 
estimated to be 10% to 20% (18), we defined RSTRs as those with 
negative TST/IGRA testing.
Figure 1. Comparison of RSTR and LTBI gene expression in whole blood and monocytes from Ugandan household Mtb contacts and from gold miners 
in South Africa. RNA from whole blood of Ugandan and South African donors was analyzed by RNAseq. (A and B) Differential gene expression between 
RSTR and LTBI donors were compared after exclusion of the indicated samples. (C and D) CD14+ monocytes were purified from cryopreserved PBMCs and 
differentiated in M-CSF for 48 hours before RNA isolation and sequencing. In Uganda, 50 subjects were included in both analyses (26 RSTR, 24 LTBI), 
while additional unique subjects were included in the monocyte (12 RSTR and 16 LTBI) and whole blood (5 RSTR and 4 LTBI) analyses. In South Africa, 39 
of 40 subjects included in the whole blood analysis were also included in the monocyte analysis. Volcano plots identify no single genes that were signifi-
cantly (FDR < 0.2) differentially expressed between RSTR and LTBI subjects in either population in the whole blood (B) and monocyte (D) analyses.
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quency of CD14+ cells, T cell subsets, NK cells, or B cells in PBMCs 
isolated from Ugandan donors when measured by flow cytome-
try (23 RSTR versus 23 LTBI subjects, Supplemental Figure 3). In 
summary, RSTR and LTBI subjects showed no differences in global 
gene transcription or frequency of cellular subsets in whole blood.
Metabolic gene programs are enriched among RSTR monocytes 
across cohorts. We next hypothesized that monocytes regulate TST/
IGRA conversion due to their potential to regulate early Mtb clear-
ance or T cell priming in highly exposed subjects. CD14+ mono-
cytes were isolated from PBMCs obtained from RSTR (Uganda n = 
38; South Africa n = 26) and LTBI (Uganda n = 40; South Africa n = 
29) subjects from which RNA was isolated and examined by RNA 
sequencing (Figure 1C). Both demographic characteristics and 
exposure scores were similar between RSTR and LTBI donors in 
Uganda (Supplemental Table 5) whereas in South Africa, ethnicity 
associated with RSTR status (P = 0.003, Supplemental Table 6). 
Accordingly, we performed all analyses stratified by ethnicity and 
present results according to the dominant ethnic group (Figure 
1C). Using multidimensional scaling (MDS), we found no evidence 
of batch effects nor any global influence of age or other available 
metadata when plotting the first 2 dimensions (Supplemental Fig-
ures 4 and 5). We found no differentially expressed genes (DEGs) 
in either cohort after multiple testing correction (FDR < 0.2; Fig-
ure 1D and Supplemental Tables 7 and 8).
We next examined whether additive biologic effects of gene 
networks differed in the LTBI or RSTR transcriptomes using a 
competitive gene set test, CAMERA (30), which is analogous to 
gene set enrichment analysis (GSEA) (31). Using approximately 
virulence and the host response (19–24); our findings suggest that 
RSTRs have differential fatty acid responses that may impact bas-
al metabolic activities to restrict TST/IGRA conversion.
Results
RSTR and LTBI subjects have similar blood transcriptional profiles 
and cellularity. Blood transcriptional profiles have successfully dis-
tinguished asymptomatic Mtb infection from Mtb disease (25–28). 
We asked whether blood transcriptomes could distinguish RSTR 
from LTBI phenotypes among TB household contacts in Uganda 
and among gold miners in South Africa. Using RNA sequencing, we 
compared whole blood transcriptomes from donors in Uganda (31 
RSTR versus 28 LTBI subjects) and South Africa (22 RSTR versus 24 
LTBI subjects; Figure 1A). Demographic and epidemiologic charac-
teristics between RSTR and LTBI were similar in Uganda includ-
ing the Mtb exposure score (Supplemental Table 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI140073DS1), whereas in South Africa (Supplemental Table 2), 
ethnicity significantly associated with RSTR status (P = 0.003). 
We stratified subsequent South Africa analyses according to the 
dominant ethnic group. After adjusting for multiple comparisons, 
no genes were significantly differentially expressed between RSTR 
and LTBI phenotypes in either population (false discovery rate 
[FDR] <0.2; Figure 1B and Supplemental Tables 3 and 4). Using 
immunoStates deconvolution (29), we found minimal, if any, dif-
ferences in the computationally predicted frequencies of cellular 
populations between RSTR and LTBI donor blood (Supplemental 
Figures 1 and 2). Furthermore, we found no difference in the fre-
Figure 2. Differentially expressed gene sets in RSTR versus LTBI donors are shared across the Ugandan and South African cohorts. (A) Using the CAMERA 
gene set test (30) on curated gene sets available from the Molecular Signatures Database (MSigDB, C2 and C7), many transcriptional programs were enriched 
(FDR < 0.01) with RSTR or LTBI phenotypes in Uganda (n = 2313 gene sets) and in South Africa (n = 606 gene sets). Among the gene sets with enrichment in 
both populations (n = 415), type 1 interferon–driven transcriptional responses enriched among RSTR and LTBI donors whereas genes involved in metabolic 
programs (e.g., oxidative phosphorylation, TCA cycle) uniformly had higher expression among RSTR donors. (B) Similar enrichment of metabolic programs 
among RSTR donors across cohorts was also identified when gene sets curated by GO terms were analyzed by CAMERA (MSigDB, C5).
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modules identified by Xue et al. (33) who stimulated MDMs with 
diverse activation signals including type I and type II IFN, proin-
flammatory and antiinflammatory cytokines, glucocorticoids, 
TLR ligands, lipoproteins, and FFAs. Using CAMERA to analyze 
these 49 macrophage activation modules, we found significant 
enrichment of multiple modules with the RSTR phenotype (Sup-
plemental Tables 11 and 12). Among 33 macrophage stimulation 
modules that were enriched in Uganda (FDR < 0.0001), 4 were 
also enriched in South Africa (FDR < 0.001; Figure 3A). These 
4 overlapping modules included genes with higher expression 
among RSTR (as compared with LTBI) monocytes (Sets 27, 26, 
06, and 24; Figure 3B).
To identify the cellular processes represented by these 4 over-
lapping transcriptional modules, we next evaluated which mac-
rophage stimuli most significantly contributed to each module. 
Correlation between each module eigengene and each original 
macrophage stimulus reported by Xue et al. (33) are depicted in 
Supplemental Figure 6. Clustering of these stimuli suggested that 
the expression pattern in resting monocytes from RSTRs was most 
influenced by the cellular responses to FFAs. Specifically, several 
modules had strong, positive correlation with long-chain FFA ole-
ic acid (OA) and linoleic acid (LiA) (Sets 6, 24, and 26) or with lau-
ric acid (LA) and high-density lipoprotein (HDL) (Set 27). Genes 
within these modules had higher expression among RSTR resting 
monocytes, which indicates that metabolic pathways influenced 
by OA/LiA (and LA/HDL) may play a role in the resistance phe-
notype. Taken together, these data suggest differential metabolic 
activities between RSTR and LTBI monocytes that relate to the 
cellular response to FFAs.
10,000 curated gene sets from the Molecular Signatures Data-
base (MSigDB) (31, 32), we identified 2313 gene sets in monocytes 
from Ugandan participants and 606 gene sets in monocytes from 
South African participants, with enrichment for either the RSTR 
or LTBI phenotypes (FDR < 0.01). Strikingly, 415 of these enriched 
gene sets were common across populations (Figure 2A and Supple-
mental Table 9). Importantly, the direction of enrichment of these 
overlapping gene sets was consistent across both populations. 
Several cellular pathways associated with each clinical phenotype, 
including the IFN-α/β response (n = 31 gene sets) and mitochon-
drial respiration or carbon metabolism (n = 32 gene sets). Genes 
involved in the TCA cycle or oxidative phosphorylation uniformly 
had higher expression in RSTR as compared with LTBI monocytes 
(Supplemental Table 9, direction ‘UP’). Finally, using gene sets 
derived from gene ontology (GO) terms (MSigDB C5 collection), 
CAMERA gene set enrichment identified a total of 64 overlapping 
biologic pathways (FDR < 0.01; Figure 2B and Supplemental Table 
10). Many of these GO terms (25 of 64) related to mitochondrial 
respiration or oxidoreductase activities in addition to other met-
abolic processes. Overall, these results identify conserved tran-
scriptional programs that underly Mtb resistance in the Ugandan 
and South African cohorts and suggest distinct metabolic activi-
ties or activation states.
Gene set enrichment suggests distinct fatty acid activation states 
in RSTR monocytes. To better define macrophage activation 
states that distinguish RSTR monocytes, we evaluated wheth-
er transcriptional modules related to a panel of macrophage 
stimuli are enriched among RSTR versus LTBI monocytes. We 
examined 49 gene sets derived from WGCNA transcriptional 
Figure 3. Gene sets derived from FFA-stimulated macrophages are consistently enriched among RSTR donors across the Ugandan and South African 
cohorts. Gene sets related to a variety of macrophage stimuli were obtained from previously published weighted gene coexpression analysis (WGCNA) 
modules (33). Enrichment among RSTR vs. LTBI transcriptomes in any of these 49 WGCNA modules was analyzed using CAMERA gene set enrichment 
(30). (A) All modules with significant enrichment in South Africa were also enriched in Uganda (FDR < 0.001). (B) The correlation plot compares P values 
from CAMERA enrichment scores in Uganda (x axis) versus South Africa (y axis) and indicates the corresponding direction of enrichment with RSTR 
phenotype (red) or LTBI phenotype (blue). This enrichment direction among Ugandan monocyte donors (color of data point) and among South African 
monocyte donors (color of module number) is highly concordant. Gene sets that correlate to macrophage FFA stimulations (Set 27, Set 6, Set 24, Set 26) 
were enriched among RSTR donors in Uganda and South Africa.
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In addition to effects on proinflammatory responses, PA 
modulates multiple macrophage pathways that include the 
inhibition of the AMPK (37), a central energy-sensing serine/
threonine kinase that promotes catabolic processes in response 
to low AMP/ATP ratios. To evaluate whether rescuing AMPK 
activity would restore control of intracellular Mtb growth in 
PA-treated macrophages, we treated Mtb-infected MDMs with 
PA (100 μM) in the presence or absence of a potent AMPK 
activator (A 769662). At nontoxic A 769662 doses (100–200 
μM), AMPK activation limited Mtb growth in a dose-depen-
dent manner, restoring growth restriction to levels observed in 
cells not treated with PA (Figure 6A). PA-mediated inhibition 
of AMPK results in potentiation of LPS-induced NLRP3 inflam-
masome activation (37). However, in the context of Mtb-infect-
ed cells, PA had inhibitory effects on IL-1β secretion (Figure 
5B), and control of intracellular Mtb growth in U937 cells was 
independent of NLRP3 (and NLRC4; Figure 6B). These data 
suggest that PA targets pathways independent of AMPK-me-
diated NLRP3 activation. AMPK also regulates autophagy by 
directly phosphorylating ULK1, which catalyzes an initiation 
complex for LC3 conjugation and autophagosome formation, 
activities that are inhibited by PA (37). However, the PA effects 
on intracellular Mtb growth restriction were independent of 
ULK1 in U937 cells (Figure 6B). In summary, PA disrupts pro-
tective macrophage proinflammatory cytokine responses and 
results in a reduced capacity to restrict Mtb growth, which can 
be restored through AMPK activation.
PRKAG2 polymorphisms are associated with resistance to TST/
IGRA conversion. Since FFA transcriptional signatures distinguished 
RSTR and LTBI monocytes, and AMPK activity modulated FFA 
effects on intracellular Mtb growth, we next explored a direct link 
between AMPK and the Mtb resistance phenotype. We used a genet-
ic approach to examine whether polymorphisms in AMPK subunit 
genes are associated with resistance to TST/IGRA conversion. This 
complex is comprised of a catalytic α-subunit and regulatory β- and 
γ-subunits, each of which has multiple isoforms (38). We examined 
257 SNPs within the 7 genes that encode the α-subunit isoforms 
(PRKAA1 and A2), the β-subunit isoforms (PRKAB1 and B2), and the 
γ-subunit isoforms (PRKAG1, G2 and G3) for associations with RSTR 
PA, but not OA, potentiates intracellular Mtb growth and modu-
lates macrophage cytokine responses. OA and PA are the 2 the most 
abundant circulating FFAs in humans and have distinct, or even 
antagonistic, immunomodulatory properties (34). Interestingly, 
the only Xue et al. (33) gene module with significant enrichment 
(FDR < 0.15) among LTBI monocytes across the Ugandan and 
South African cohorts (Set 7; Figure 3B) consists of a macrophage 
gene expression profile that correlates with PA and IFN-γ stimu-
lation. We next hypothesized that the early cellular Mtb response 
would differ in OA- versus PA-treated macrophages, considering 
that the transcriptional patterns following stimulation with these 
FFA species overlaps with resting RSTR versus LTBI monocytes, 
respectively. Mtb-infected healthy-donor MDMs were treat-
ed with OA and PA complexed to bovine serum albumin (BSA), 
which is required for solubilization. Intracellular Mtb growth was 
potentiated by PA in a dose-dependent manner, whereas OA had 
minimal effect (Figure 4A). PA and OA were minimally toxic to 
macrophages at these doses (Supplemental Figure 7A). PA was 
toxic at doses greater than or equal to 400 μM (36% cell death) 
yet further potentiated intracellular Mtb replication despite this 
reduced macrophage viability (Supplemental Figure 7B). Both 
PA and OA are mycobacterial carbon sources yet have also been 
associated with direct microbicidal activity (35, 36). In 7H9 broth, 
neither PA nor OA had pronounced effects on Mtb growth (Fig-
ure 4B), suggesting that PA most likely modulates macrophage 
function or perhaps influences Mtb nutrient acquisition within the 
macrophage environment.
To explore the mechanisms by which PA enhances Mtb growth 
within macrophages, we first compared effects of OA and PA on 
macrophage cytokine production in response to antigens present 
in Mtb whole cell lysate (TBWCL). Both OA and PA potentiated 
TNF secretion and inhibited IL-10 secretion in a dose-dependent 
manner, whereas only PA robustly potentiated IL-1β secretion at 
doses greater than or equal to 200 μM (Figure 5A). In contrast, 
proinflammatory cytokine secretion by Mtb-infected macro-
phages was inhibited by PA (Figure 5B) while OA had no effect. 
The inhibitory effect on proinflammatory cytokine secretion from 
Mtb-infected macrophages suggests a possible mechanism where-
by PA limits the macrophage capacity to restrict Mtb growth.
Figure 4. Control of intracellular Mtb growth is lost in PA-treated macrophages. (A) Human MDMs were infected with a reporter Mtb Erdman strain (Mtb-lux) 
for 4 hours (MOI = 2), washed, then treated with PA, OA, or vehicle controls that were matched for BSA content. (B) Mtb-lux was diluted in complete 7H9 
media containing indicated concentrations of OA, PA, matched BSA controls, or 0.5 μg/mL rifampin (RIF) to an OD approximately 0.005. Replication was mea-
sured as RLUs after 3 days in each experiment. Means are plotted for biologic replicates (A, n = 5 replicates; B, n = 3 replicates) along with standard deviation 
(error bar). Effects are representative of more than 5 independent experiments using a total of 2 donors (A, macrophages), or of 2 independent experiments 
(B); a simple linear model was applied to test for significant dose-dependent effects on Mtb growth. NS, P > 0.05; **P < 0.01; ****P < 0.0001.
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(n = 74 genotyped subjects) or LTBI (n = 189 genotyped subjects) phe-
notypes among Ugandan household contacts (7). Seven SNPs within 
PRKAG2 were strongly associated with RSTR status (OR 1.9–3.2, P 
< 0.005; Table 1) using an additive genetic model adjusted for kin-
ship, sex, and age. Inheritance of 2 copies of the minor allele further 
increased the association with RSTR status with odds ratios ranging 
from 3.3 to 18.5 (Supplemental Table 13, recessive model). When 
corrected for false discovery, 3 of the 7 SNPs remained significant 
(FDR < 0.05; rs10480299, rs10480300, rs114166988), all of which 
are in moderate linkage disequilibrium, suggesting a single causative 
locus (Supplemental Table 14). These results suggest that genetic 
variation in a central regulator of metabolism is associated with the 
RSTR outcome and is highly consistent with our ex vivo monocyte 
transcriptomic profiling findings. Moreover, the previously described 
inhibition of AMPK by PA (37), which we demonstrate enhances 
intracellular Mtb growth, further implicates differential AMPK activ-
ity in monocyte responses between RSTR and LTBI contacts.
Discussion
Protective mechanisms that restrict TST/IGRA conversion in high-
ly exposed contacts are not defined. Our study suggests that RSTR 
and LTBI populations have distinct monocyte transcriptional pro-
Figure 5. OA and PA modulate mac-
rophage cytokine responses, but 
only PA restricts proinflammatory 
cytokines following Mtb infection. 
Healthy human MDMs were treated 
with the indicated doses of PA, OA, 
or controls matched for BSA content 
overnight and then stimulated with 
(A) Mtb whole cell lysate (TBWCL), 
(B) infected with live Mtb (5 CFU per 
cell), or left unstimulated. Cytokine 
secretion was quantitated by ELISA 
from supernatants at 24 hours after 
stimulation. Means are plotted 
for biologic replicates (A, n = 2 or 3 
replicates; B, n = 3 replicates) along 
with standard deviation (error bar). 
Effects are representative of 2 inde-
pendent experiments from a single 
donor. Data were fit using a simple 
linear model to test for a significant 
dose-dependent effect and were 
log-transformed as necessary to 
achieve the best regression fit. NS, 
P > 0.05; *P < 0.05; ***P < 0.001; 
****P < 0.0001.
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files that relate to differences in metabolic pathways and the cellu-
lar response to FFAs. Transcriptional profiles of OA-conditioned 
macrophages were enriched in RSTR as compared with LTBI 
monocytes. Consistent with their known opposing activities on 
inflammatory pathways, we found that PA and not OA enhanced 
Mtb growth within macrophages that may relate to distinct intra-
cellular Mtb control pathways in RSTR and LTBI individuals. In 
mechanistic support of these exploratory findings, we identify 
AMPK polymorphisms that strongly associate with the RSTR 
phenotype and found that pharmacologic restoration of AMPK 
function abrogates PA-mediated cellular effects on Mtb growth 
in vitro. Taken together, our study suggests that RSTR monocytes 
have distinct metabolic activities that mediate resistance to TST/
IGRA conversion and identify AMPK as a potential regulator.
Immunometabolic pathways are central to host-Mtb interac-
tions and regulate infection outcomes (24, 39–43). Several reports 
indicate that Mtb induces macrophage glycolysis to its benefit (24, 
44), whereas macrophage subtypes that are skewed toward glyco-
lytic metabolism are less permissive to Mtb in vivo (22). The shift 
away from oxidative phosphorylation and toward aerobic glycolysis 
is a hallmark of macrophage activation by TLR ligands and IFN-γ 
(45, 46), and is linked to host-protective mechanisms regulated by 
HIF-1α (21, 42, 47). Our gene set enrichment analyses identified 
multiple gene sets linked to mitochondrial respiration and the TCA 
cycle and these genes collectively had higher expression among 
resting RSTR relative to LTBI monocytes. Interestingly, a whole 
blood transcriptional signature that most strongly predicted treat-
ment failure among subjects with Mtb disease included suppressed 
mitochondrial genes prior to treatment initiation (48), which sug-
gests that adequate expression levels may reflect a host response 
that not only correlates with resistance to infection but also respon-
siveness to treatment. Whether the association of oxidative phos-
phorylation gene sets among RSTR cells translates to a differential 
flux through the mitochondrial electron transport chain, or if such 
perturbations are also differentially regulated in RSTR versus LTBI 
monocytes after infection with Mtb, is a focus of future studies.
Our second major finding genetically links the RSTR pheno-
type to a central metabolic regulator. This locus (chromosome 
7q36.1), encoding the AMPK-γ subunit, has not previously been 
associated with the RSTR phenotype. However, these PRK-
AG2 SNP associations are of a similar confidence (P = 0.0003–
0.00001) as previously identified genetic loci that associate with 
resistance to TST conversion, accounting for differences in study 
design (49–53). Additional studies are required to determine the 
functional PRKAG2 SNPs, whether they increase or decrease 
AMPK activity, and characterize the downstream immunomet-
abolic effects that may contribute to resistance to Mtb infection. 
Of interest, multiple host-directed therapies that enhance macro-
phage restriction of Mtb intracellular growth are known to posi-
tively regulate activity of AMPK-linked pathways including met-
formin (43), sirtuin-1 activators (19, 54), and AICAR (55). We also 
found AMPK activation with A 769662 restricted Mtb growth in 
macrophages (Figure 5A). Notably, metformin use (and by exten-
sion perhaps AMPK activation) has also been associated with 
reduced prevalence of LTBI, which suggests activity that restricts 
incident infection in vivo (56, 57). Additional studies are required 
to directly determine whether AMPK activity differs in primary 
cells isolated from RSTR and LTBI subjects.
We also found that gene sets related to FFA stimulation were 
differentially enriched in RSTR versus LTBI monocytes under 
resting conditions. Interestingly, metabolomic signatures of medi-
um-chain and long-chain fatty acid plasma concentrations were 
Figure 6. Control of intracellular Mtb growth in PA-treated macrophages is 
restored by AMPK activation. (A) Healthy human donor MDMs were infected 
with a reporter Mtb Erdman strain (Mtb-lux) for 4 hours (MOI = 2), washed, then 
treated with 100 μM PA alone or in combination with the indicated doses of the 
AMPK activator A 769669. (B) U937 monocytes with disruptions in inflammasome 
genes (encoding NLRP3 or NLRC4), an autophagy gene (ULK1), or control cell lines 
expressing nontargeting guide RNAs were generated by CRISPR-Cas9 technology, 
differentiated in PMA and infected with Mtb-lux as in (A), then treated with 200 
μM PA or BSA vehicle control. RLUs were recorded at 3 days after infection (A and 
B); mean RLU of 5 biologic replicates are plotted with standard deviations (error 
bars). Findings are representative of 2 independent experiments (A, B) from a 
single donor (A). The effect of AMPK activation on Mtb-lux growth in PA-treated 
cells was significant as determined by (A) 1-way ANOVA (P < 0.0001), where P 
values were then calculated for the indicated pairwise comparisons and adjusted 
using Tukey’s multiple comparison test. P values for single-dose PA effects were 
calculated by 2-tailed t test (B). ***P < 0.001; ****P < 0.0001.
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may relate to the association of diabetes 
mellitus with Mtb disease susceptibility 
(65). While our transcriptional data identify 
expression patterns in metabolic pathways 
and not metabolite levels, serum profiling 
of OA and PA levels in RSTR versus LTBI 
subjects remains of future interest.
The specific mechanism by which PA 
enhances intracellular Mtb growth remains 
to be identified. PA is known to inhibit 
autophagy by limiting AMPK-mediated 
activation of ULK1 as measured by auto-
phagosome formation, microtubule-as-
sociated protein 1 light chain 3 (LC3) lip-
idation and LC3 puncta formation (37). 
Although the enhanced intracellular Mtb 
growth in PA-treated cells was maintained 
in ULK1-deficient THP-1 cells (Figure 6B), 
a role for PA in modulating autophagy has 
not been excluded considering AMPK acti-
vation restored growth restriction (Figure 
6A) and is known to activate ULK1 and 
ULK2, which have the redundant function 
in autophagosome initiation (66). Alter-
natively, LC3-associated phagocytosis 
(LAP) is independent of ULK1 and could 
be modulated by PA (67). Our data also 
remain consistent with a host-protective 
role for AMPK activation in reversing the 
deleterious effects that PA has on separate 
pathways that may impact Mtb control, such as increased ceramide 
synthesis/lipotoxicity (68, 69) and resultant ER stress (70, 71); 
mitochondrial dysfunction, including the generation of reactive 
oxygen species (ROS) (72, 73) and the disruption of FFA beta-ox-
idation (74); or effects on macrophage polarization and cytokine 
responses (75, 76). Many of these PA effects are antagonized by 
monounsaturated fatty acids including OA (34, 68, 76–78), which 
correlates with our RSTR versus LTBI transcriptional dichotomy. 
While prior studies using differentiated THP-1 cells found that 
preinfection OA treatment restricted intracellular Mtb (79), we 
found no OA effect on MDMs treated immediately after infection. 
Parihar et al. (80) also reported that pretreatment of murine bone 
marrow–derived macrophages with OA restricted intracellular Mtb 
growth, whereas PA had minimal effects at high doses (500 μM), 
suggesting our findings may be specific to human primary macro-
phages and highlighting the potential importance of the timing of 
FFA treatments.
We found that both PA and OA modulated host cytokine 
responses following Mtb whole cell lysate stimulation whereas only 
PA impacted these responses within Mtb-infected cells (Figure 5). 
Strikingly, PA had opposing effects that were dependent on Mtb 
viability where proinflammatory cytokine secretion increased after 
Mtb whole cell lysate stimulation but decreased in Mtb-infected 
cells. Under cellular conditions that promote glycolysis in macro-
phages (e.g., after TLR stimulation), IL1B transcription increases 
resulting in host-protective effects like CFU reduction (21). Recent 
work demonstrates that live Mtb attenuates IL1B transcription 
elevated among Mtb household contacts in the Gambia who con-
verted TST/IGRA testing as compared with nonconverters, both 
initially after exposure and after 3 months of follow-up (11). Host 
metabolomic signatures that distinguish subjects with Mtb disease 
versus healthy contacts (58) and that predict progression from LTBI 
to active Mtb disease (59) also have included medium- and long-
chain FFAs. Lipid metabolism lies at an interface between host 
and pathogen responses within macrophages (60). Mtb acquires 
host lipids and cholesterol as carbon sources (61–63) and access 
to these nutrients may be restricted as part of the IFN-γ–primed 
host response (64). Furthermore, virulent Mtb shifts mitochondri-
al dependency from glucose to exogenous fatty acids in primary 
human macrophages whereas avirulent or dead Mtb promotes gly-
colytic flux (20), suggesting these macrophage metabolic switches 
may be linked to virulence of the invading pathogen. We identified 
multiple independent macrophage gene programs downstream of 
OA (and linoleic/lauric acid) stimulation that strongly enriched 
among RSTR monocyte transcriptomes, whereas a single gene 
set (Set 7) that enriched among LTBI subjects correlates with the 
macrophage transcriptional response to PA (33). This dichotomy of 
gene programs between RSTR and LTBI monocytes parallels the 
opposing biologic effects of OA and PA, which are among the most 
abundant circulating FFAs. Since PA treatment of healthy donor 
macrophages enhanced intracellular Mtb replication, our com-
bined results suggest that host-protective pathways are negatively 
influenced by PA. Interestingly, insulin sensitivity is also negatively 
impacted by an elevated plasma PA/OA ratio (34), an effect that 
Table 1. Polymorphisms in PRKAG2, which encodes a regulatory AMPK subunit,  
are associated with the RSTR phenotype in Uganda
Genotype frequency
SNP Genotype RSTR (case) LTBI (control) ORA (95% CI) P value FDR
rs10480299 T/T 0.311 0.556 2.78 (1.77–4.38) 1.00 × 10–5 2.6 × 10–3
T/C 0.500 0.407
C/C 0.189 0.037
rs10480300 C/C 0.500 0.693 2.48 (1.51–4.05) 3.16 × 10–4 2.7 × 10–2
C/T 0.378 0.291
T/T 0.122 0.016
rs114166988 T/T 0.554 0.751 2.64 (1.56–4.49) 3.18 × 10–4 2.7 × 10–2
T/C 0.351 0.243
C/C 0.095 0.005
rs10224002 A/A 0.274 0.439 1.94 (1.29–2.91) 1.40 × 10–3 9.0 × 10–2
A/G 0.425 0.433
G/G 0.301 0.128
rs56145758 T/T 0.757 0.905 3.22 (1.51–6.88) 2.56 × 10–3 0.12
T/A 0.216 0.095
A/A 0.027 0.000
rs115310513 A/A 0.757 0.894 2.98 (1.46–6.08) 2.69 × 10–3 0.12
A/G 0.203 0.106
G/G 0.041 0.000
rs1860746 C/C 0.541 0.693 2.27 (1.31–3.93) 3.51 × 10–3 0.12
C/A 0.392 0.291
A/A 0.068 0.016
AOR indicates additive odds for being a case (RSTR) compared with control (LTBI) for each copy of the 
minor allele inherited (additive model).
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between 2002 to 2012 as part of the Kawempe Community Health Study 
(Kampala, Uganda) for serial TST testing (8), and a subset of these house-
hold contacts were successfully recontacted after 8 to 10 years for PBMC 
collection and to complete serial IGRA and repeat TST testing (7).
The Highly Exposed TB Uninfected (HETU) study was a pro-
spective, longitudinal study of HIV-negative gold miners who were 
screened between August 2015 and December 2016 in North West 
Province, South Africa (our unpublished observations). Subjects who 
had worked in the mining industry for 15 years or more, were aged 33 
to 60 years, had no history, symptoms, nor prior treatment of TB, and 
no silicosis were eligible. Subjects underwent Quantiferon-TB Gold 
In-Tube (QFT-GIT, Qiagen) and TST (Matoux method, 5 tuberculin 
units of PPD, Statens Serum Institute) evaluations at baseline. RSTR 
gold miners had concordant negative TST (<5 mm in duration) and 
negative QFT-GIT (as defined by manufacturer) testing at enrollment. 
At enrollment, PBMCs were collected and isolated by Ficoll gradient, 
cryopreserved, and shipped to Seattle, Washington, USA, along with 
whole blood frozen in PAXgene RNA tubes (Qiagen).
Details, including RSTR case definitions, are published for the 
Ugandan cohort (7, 8) and are available in Supplementary Materials.
Cell culture, reagents, and mycobacterial strains. Roswell Park 
Memorial Institute 1640 medium (RPMI 1640, Gibco) was supple-
mented with FBS (Atlas Biologicals) to a final concentration of 5% 
(RPMI-5) or 10% (RPMI-10). Macrophage colony-stimulating factor 
(M-CSF) was purchased from Peprotech. PA (catalog P5585), OA (cat-
alog O1383), and fatty-acid free BSA (catalog A7030) were purchased 
from MilliporeSigma. A 5% (wt/vol) BSA solution in 1× PBS (Gibco) 
was filter-sterilized and stored up to 3 months at 4°C and used to 
solubilize FFAs. The endotoxin content of this solution was negligi-
ble (<0.2 pg endotoxin per 1 mg BSA) as confirmed by limulus assay 
(Lonza). The AMPK activator “A 769669” was purchased (Tocris Bio-
science), reconstituted in DMSO (50 mM), and aliquots were stored 
(–80°C) until final dilutions were prepared in RPMI/5.
U937 cells (ATCC CLR1593) with disruptions in NLRP3 and 
NLRC4 were generated using CRISPR/Cas9 by lentivirus delivery 
of guide RNAs (Supplementary Materials), selected in puromycin 
(83) as described for ULK1 (84), and screened phenotypically and by 
sequencing. Prior to each experiment, these U937 cells were differen-
tiated for 72 hours in phorbol 12-myristate 13-acetate (PMA, Invitro-
gen), washed, and rested overnight in RPMI/10 without PMA before 
infection or stimulation.
The Mycobacterium tuberculosis Erdman reporter strain expressing 
the luxCDABE operon from Vibrio harveyi (Mtb-lux) was a gift of Jeff 
Cox (University of California at Berkeley) and was grown in Middle-
brook 7H9 media supplemented with glycerol (Fisher; 4 mL/L), albu-
min-dextrose-catalase (ADC) supplement (Middlebrook, 100 mL/L) 
and Tween 80 (Fisher; 0.05% final). We previously demonstrated a 
linear correlation between relative light units (RLUs) and colony form-
ing units (CFUs) using this strain (85).
Monocyte isolation, RNA isolation. Cryopreserved PBMCs were 
thawed, washed, and resuspended at 2 million cells per milliliter in 
RPMI-10 supplemented with M-CSF (50 ng/mL), then rested over-
night. CD14+ monocytes were isolated by magnetic bead column puri-
fication using negative selection (Monocyte Isolation Kit II, Miltenyi 
Biotec) and then plated at 1 million cells per milliliter RPMI-10 supple-
mented with M-CSF in duplicate wells. After 24 hours (~48 hours total 
M-CSF exposure), media were removed and cells were lysed in Trizol 
(relative to heat-killed Mtb) by exploiting a host pathway that neg-
atively regulates glycolysis (81). Our results are consistent with a 
mechanism whereby PA and viable Mtb interact to restrict the IL-1β 
response at the transcriptional level, even as PA enhances TLR-in-
duced IL-1β via posttranslational NLRP3 activation (Figure 5A and 
ref. 37). Further studies are required to demonstrate whether this 
PA-Mtb interaction results in modulation of glycolysis or other met-
abolic pathways to restrict proinflammatory cytokine secretion.
Our study has several limitations, including those related to 
LTBI diagnostics that define the RSTR phenotype. Mechanisms 
that underly resistance to TST/IGRA conversion could reflect 
(a) inadequate exposure, (b) early clearance of the pathogen via 
innate immune cell functions that precede T cell priming (10, 
82), (c) clearance of Mtb through antigen-specific CD4+ T cell or 
other adaptive responses that are independent of IFN-γ (4), or (d) 
persistent paucibacillary infection that fails to prime IFN-γ–pro-
ducing, antigen-specific T cell responses but otherwise may be 
indistinguishable from LTBI. Emerging evidence from the same 
Ugandan RSTR cohort studied here indicates these subjects are 
indeed Mtb-exposed as determined by both epidemiologic param-
eters (7, 8) and alternative (IFN-γ–independent) immune sensiti-
zation (4). In addition, our analyses identified transcriptional 
differences in unstimulated RSTR and LTBI monocytes. Whether 
this extends to differences in metabolite levels in vivo or changes 
in metabolic flux after ex vivo Mtb infection is an important focus 
of future studies. Transcriptional differences in unstimulated 
monocytes may suggest distinct epigenetic programing that can be 
specifically evaluated using existing platforms (e.g., methylation 
profiling, ATACseq). The transcriptional differences identified 
here in peripheral blood also incentivize the collection of alveo-
lar macrophages; these cells are the earliest targets of Mtb in vivo, 
with distinct metabolic activities and the potential to dramatically 
influence innate and cellular responses that distinguish RSTR and 
LTBI outcomes. Similarly, it will be important to confirm whether 
the PA effect on Mtb replication within MDMs is also seen in other 
primary myeloid cell types, including alveolar macrophages and 
dendritic cells that have distinct ontogeny or differentiation path-
ways that may involve metabolic programming (22). 
In summary, we report that transcriptional programs are dis-
tinct in monocytes from RSTR and LTBI donors. These differences, 
especially those conserved across 2 distinct RSTR populations, give 
insight into the early Mtb response in subjects who resist TST and 
IGRA conversion and implicate distinct metabolic programs. Fur-
thermore, we identify polymorphisms in the central metabolic reg-
ulator AMPK that are associated with RSTR individuals. Additional 
work is required to define the protective mechanisms of these met-
abolic pathways in hopes they may be amplified by host-directed 
therapies that could augment current antimicrobial therapy.
Methods
Subject recruitment. Our study involved ex vivo characterization of whole 
blood and monocytes isolated from highly Mtb-exposed, HIV-negative 
donors in Uganda and South Africa. We hypothesized that donors who 
resisted TST/IGRA conversion would have distinct transcriptional signa-
tures as compared with control donors with LTBI and that these differ-
ences may inform mechanistic hypotheses. Ugandan household contacts 
of index cases with culture-confirmed pulmonary TB were recruited 
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tics) and BCA assay (Thermo Fisher Scientific). After dilution of 
FFA/BSA complexes in RMPI-5, the ratio for each 200 μM solution 
was measured to be 1.2:1.
Intracellular monocyte-derived macrophage replication. Human 
MDMs were prepared from LRS TRIMA chambers harvested from 
healthy donors (Bloodworks Northwest). CD14+ monocytes were iso-
lated and differentiated in RPMI-10 plus 50 ng/mL M-CSF for a total 
of 6 to 7 days prior to infection. Log-phase (OD < 0.6) Mtb-lux cultures 
were applied to a 5-μm syringe filter (Millipore) to achieve a single-cell 
suspension, diluted in RPMI, and added to MDM cultures (MOI = 1–2 
CFU per cell). Following a 4-hour infection, monolayers were washed 
twice with warm RPMI, and then returned to fresh RPMI-5 media con-
taining M-CSF and the indicated doses of FFA or controls matched for 
BSA content. Luminescence was recorded using a Synergy H4 mul-
timode microplate reader (Biotek Instruments). PMA-differentiated 
U937 cells were similarly infected, then treated with 200 μM PA.
Cytokine secretion. Human MDMs were prepared from LRS TRI-
MA chambers as above, treated overnight with FFAs, and then stim-
ulated with Mtb (H37Rv) whole cell lysate (25 μg/mL; BEI Resourc-
es), live Mtb-lux filtered as above (MOI = 5 CFU per cell), or media 
control in the presence of FFA. Supernatants were harvested at 24 
hours after stimulation and those containing infectious Mtb were 
filtered to remove them from BSL-3, after which cytokine concen-
trations were assayed by DuoSet ELISA (R&D Systems) using TMB 
peroxidase substrate (SeraCare) and read on a SpectraMax-Plus 
plate reader (Molecular Devices).
Macrophage viability assay. Human MDM viability after PA, OA, 
and BSA vehicle control was quantitated using the IncuCyte live cell 
analysis system (Sartorius). Healthy donor MDMs were treated with 
the indicated final concentrations of each fatty acid and Sytox Green 
nucleic acid stain diluted according to the manufacturer’s specifica-
tions (Thermo Fisher Scientific) and immediately imaged over 72 
hours. Cell death was quantitated as the proportion of cells with nucle-
ar green fluorescence divided by the average Syto Green–positive 
(Thermo Fisher Scientific) cells stained in control wells. Fluorescence 
signal decayed after approximately 48 hours, so the peak signal was 
used to estimate cell death (%).
AMPK isoform candidate gene association study. Using the Illumina 
MEGAEX array consisting of 2 million single nucleotide polymorphisms 
(SNPs), we genotyped HIV-negative Ugandan household contacts 
defined as RSTR (n = 74) or LTBI (n = 189) as previously described (7). 
This array selected variants optimized for samples of African ances-
try. Gene regions of the 7 isoforms encoding each subunit of AMPK 
(PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3) 
were examined along with 5 kb flanking sequences defined using 
Ensembl (build GRCh37). Among these regions, there were a total of 
257 SNPs included in the Illumina MEGAEX array (12 in PRKAA1, 20 in 
PRKAA2, 2 in PRKAB1, 13 in PRKAB2, 2 in PRKAG1, 201 in PRKAG2, 
7 in PRKAG3). We compared the genotype frequency in cases (RSTR) 
and controls (LTBI) with an additive model, accounting for family 
relationships via a penalized quasi-likelihood approximation to the 
generalized linear mixed model (GENESIS), and adjusted for age and 
sex (52, 53, 91, 92). To adjust for multiple comparisons, P values were 
adjusted by FDR. For SNPs of interest (P < 0.01), we also examined 
dominant and recessive models.
Flow cytometry. Peripheral blood mononuclear cells from Ugandan 
donors (23 RSTR and 23 LTBI) were stained for viability with LIVE/
(Invitrogen) and frozen. The aqueous phase of thawed lysates were 
then collected after chloroform extraction to which 100% ethanol was 
added before applying to miRNeasy micro columns for RNA isolation 
according to the manufacturer’s instructions (Qiagen). PAXgene tubes 
were thawed at room temperature and RNA was isolated using PAX-
gene miRNA spin columns (Qiagen). Eluates were globin-depleted by 
oligonucleotide hybridization according to the manufacturer’s instruc-
tions (Ambion). RNA from both PAXgene and monocyte samples was 
quantitated by Nanodrop (Thermo Fisher Scientific) and quality was 
assessed (RIN ≥ 8.0) by Agilent TapeStation.
RNA sequencing and data processing. cDNA libraries were prepared 
using random hexamer priming and rRNA depletion according to the 
manufacturer’s specifications (Takara, SMARTer RNAseq Kit–Pico 
Input Mammalian). RNA sequencing was performed on the Illumi-
na HiSeq 2500 in high output mode, which achieved a read depth of 
30 million paired-end, 50 base pair reads. Adapters were removed 
with Cutadapt (86) prior to sequence alignment using STAR 2.6.0a 
(87) with the GRCh38 reference genome. Counts for each gene were 
assigned using RSEM 1.3.0 (88). Data were transformed with respect 
to library size using voom (89). Using multidimensional scaling 
(MDS), we found no evidence of batch effects nor any global influence 
of age or the other available metadata from each cohort when plotting 
the first 2 dimensions. In Uganda, these included family group, BMI, 
epidemiologic risk score, and BCG history (Supplemental Figure 4). In 
South Africa, these included country of origin, occupation (skilled ver-
sus unskilled labor), living arrangement (mine hostel or not), active or 
accumulative years worked underground, and ethnicity (Supplemental 
Figure 5). However, ethnicity was associated with RSTR versus LTBI 
status (Supplemental Tables 2 and 6; P = 0.003). Similarly, occupation 
level was also associated with ethnicity where skilled laborers were 
significantly more likely to be white (P < 4.8 × 10–5). Since the asso-
ciation between white ethnicity and RSTR status most likely reflects 
lower exposure among skilled as compared with unskilled laborers, all 
analyses were performed with and without inclusion of (n = 6) White 
subjects (Figure 1). Although our main findings were unchanged, 
greater overlap existed across Ugandan and South African signatures 
using this stratified analysis so these analyses are presented.
Gene set enrichment analysis. To identify enrichment of biologic 
pathways or macrophage activation states with the RSTR or LTBI clini-
cal phenotypes, we used the Correlation Adjusted Mean Rank gene set 
test (CAMERA) implemented in limma R package version 3.42.0 (30), 
which is a competitive gene set test that is similar to GSEA (31), but less 
susceptible to inter-gene correlations. We performed separate analy-
ses for each of 3 lists of gene sets: MSigDB (32) C2 and C7 (9547 gene 
sets), MSigDB C5 gene sets (n = 5914), 49 transcriptional modules 
identified by Xue et al. (modules 1–49; ref. 33). Nominal P values were 
calculated for the degree of enrichment for individual gene sets using 
CAMERA, which were then adjusted (FDR) to account for simultane-
ous comparisons. Details are available in Supplementary Materials.
Preparation of free fatty acids. PA and OA were solubilized by 
complexation with 5% BSA (MilliporeSigma) prepared in 1× PBS 
(Gibco) in a previously described method (90). These resulting 4.6 
mM FFA/BSA solutions were diluted further to desired final con-
centrations in warm RPMI-5 and filter sterilized through a 0.2 μm 
PES membrane (Millipore). Molar ratios of the 4.6 mM FFA/BSA 
complexes were experimentally confirmed to be 3:1 using a nones-
terified fatty acid–HR quantitation kit (FUJIFILM Wako Diagnos-
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DEAD Fixable Dead Cell Stain (Thermo Fisher Scientific), permeabi-
lized and fixed in FACS Permeabilizing Solution 2 (BD Biosciences), 
before staining for CD56, washed, then stained with the remaining 
antibody cocktail (Supplemental Table 15). Cells were washed, treated 
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2 mM EDTA/1× PBS at 4°C overnight. Cell counts were acquired on 
a LSRFortessa (BD Biosciences) and cell population frequencies were 
calculated using the indicated ratios. Differences in mean frequencies 
were compared (Mann-Whitney U test).
Statistics. For differential gene expression between RSTR and 
LTBI phenotypes, nominal P values were calculated and corrected for 
FDR by the Benjamini-Hochberg procedure, as implemented by the 
R package limma. FFA dose-dependent effects on Mtb growth were 
compared by fitting RLU data to a simple linear model using Prism 
8.3.1 (GraphPad Software, LLC). Data were log-transformed where 
indicated to achieve the best regression fit. Ordinary 1-way ANOVA 
was used to confirm a significant dose-dependent A 769662 inhibito-
ry effect (Figure 6A) where P values were calculated for each pairwise 
comparison and adjusted using Tukey’s multiple comparison test. For 
single-dose pairwise comparisons (Figure 6B), P values were instead 
calculated by Student’s 2-tailed t test. Study subject epidemiologic 
and demographic data were compared using Stata/IC 15.1 (StataCorp 
LLC). P values were calculated using the χ2 or Fisher’s exact tests for 
categorical variables and the Mann-Whitney U test for continuous 
variables. A P value less than 0.05 was considered significant.
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